Danish leader will face a challenging landscape among competitors ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk A/S (NVO) tumbled 22% Tuesday - The company attributed its lowered guidance in part to persistent use of ...